Individuals with type 2 diabetes who also have atrial fibrillation (AF) have a substantially increased risk of cardiovascular events and death, according to an international team of researchers (Du X et al. Eur Heart J. doi: 10.1093/eurheartj/ehp055 [published online March 11, 2009]).
The researchers analyzed data from the ADVANCE (Action in Diabetes and Vascular Disease: preterAx and diamicroN-MR Controlled Evaluation) trial, a study of more than 11 000 patients with type 2 diabetes, 7.6% of whom had AF at baseline. Participants were randomly assigned to receive a fixed combination of antihypertensive medications (perindopril and indapamide) or placebo and followed up for a mean of 4.3 years. Participants who had AF at baseline were 61% more likely than those without AF at baseline to die from any cause, 77% more likely to die from cardiovascular causes, and 68% more likely to die from major cerebrovascular events or heart failure.
Stephenson J. Arrhythmia and Diabetes. JAMA. 2009;301(15):1529. doi:10.1001/jama.2009.503